Research Associate/Senior Research Associate, Synthetic Biology

Company Summary:

Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Position Summary:

The Synthetic Biology group is seeking a Research Associate/Senior Research Associate who will support the development of novel gene editing technologies to advance programs for proof-of-concept studies. This individual will join a collaborative team and have high growth potential.

Key Responsibilities:

• Validation and execution of directed evolution & rational engineering screens
• Preparation and analysis of Next Generation Sequencing libraries
• Analysis, modelling, and presentation of large screening datasets

Basic Qualifications:

• BS/MS (non-PhD role) in biological sciences plus 0-2 years of academic or industrial research experience
• Experience with modern molecular biology techniques (ex. Gibson assembly, Golden Gate)
• Attention to detail, critical analysis of data, and good troubleshooting ability are required
• Strong written and oral communication skills, interpersonal skills and ability to effectively work as part of a team
• Flexibility to work across multiple projects at once

Preferred Qualifications:

• Experience with Next Generation Sequencing (Illumina, Nanopore, PacBio)
• Experience in mammalian cell culture
• Experience in bioinformatics &/or programing (Python/R/equivalent)

 

More About Flagship Pioneering

Flagship Pioneering has conceived of and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Editas Medicine (NASDAQ: EDIT), Omega Therapeutics (NASDAQ: OMGA), Seres Therapeutics (NASDAQ: MCRB), and Indigo Agriculture. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

 

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.